Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 445 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
445 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including NSCLC, MSS colorectal cancer, pancreatic, gastric/GEJ adenocarcinoma, or head and neck squamous cell carcinoma—with good performance status, to receive BMS-986484 (an investigational anti-FAP biologic) as monotherapy or combined with nivolumab. Eligible patients must have measurable disease by RECIST v1.1 and ECOG 0-1.
ClinicalTrials.gov ID: NCT06544655
TrialFetch AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.
ClinicalTrials.gov ID: NCT05902988
TrialFetch AI summary: This trial enrolls adults with platinum-refractory extensive stage small cell or stage IV non-small cell lung cancer previously treated with PD-1/PD-L1 inhibitors, evaluating autologous T cells engineered to express a GD2-directed CAR, IL-15 for enhanced persistence, and an inducible caspase 9 safety switch. Patients receive leukapheresis, ex vivo T cell modification, and a single infusion of this investigational CAR T cell therapy.
ClinicalTrials.gov ID: NCT05620342
TrialFetch AI summary: Eligible patients are adults with advanced solid tumors harboring a KRAS G12D mutation, measurable disease, ECOG 0-1, and prior systemic chemotherapy. The trial evaluates oral LY3962673, a selective KRAS G12D inhibitor, as monotherapy and in combination with standard chemotherapies (including agents such as FOLFOX, FOLFIRI, and gemcitabine/nab-paclitaxel).
ClinicalTrials.gov ID: NCT06586515
TrialFetch AI summary: This trial enrolls adults with locally advanced or metastatic solid tumors harboring HER2 aberrations (mutations, amplification, or overexpression) or EGFR exon 20 insertions who have progressed on standard therapies, and treats them with YH42946, an oral tyrosine kinase inhibitor targeting mutant HER2 and EGFR exon 20 insertions.
ClinicalTrials.gov ID: NCT06616766
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors linked to COX2-mediated immunosuppression who have exhausted standard therapies, including specific expansion cohorts for sarcoma, pancreatic cancer, NSCLC without driver mutations, microsatellite stable/low colorectal cancer, and head and neck squamous cell carcinoma. Patients receive OKN4395, an oral triple antagonist of EP2, EP4, and DP1 prostanoid receptors, as monotherapy or in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT06789172
TrialFetch AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (including classical, atypical, exon 20 insertion, and resistance mutations) and/or HER2 kinase domain mutations who have received standard therapies, testing the investigational oral agent BH-30643, a mutant-selective OMNI-EGFR inhibitor targeting a broad spectrum of EGFR and HER2 mutations. Patients must have measurable disease, good performance status, and no significant comorbidities or prior ILD.
ClinicalTrials.gov ID: NCT06706076
TrialFetch AI summary: Adults with advanced unresectable or metastatic melanoma (non-uveal/mucosal), head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, or classical Hodgkin lymphoma who have progressed on prior PD-1/PD-L1 therapy are eligible to receive CTX-8371, an investigational bispecific antibody targeting PD-1 and PD-L1 designed to overcome checkpoint inhibitor resistance, as monotherapy.
ClinicalTrials.gov ID: NCT06150664
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic Claudin-1 positive squamous solid tumors (including SqNSCLC, HNSCC, ESCC, or CSCC) who are refractory or intolerant to standard therapies. Patients receive ALE.P02, a CLDN1-targeted antibody-drug conjugate that delivers a tubulin inhibitor selectively to CLDN1-positive tumor cells.
ClinicalTrials.gov ID: NCT06747585
TrialFetch AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors expressing CEACAM5—including colorectal, non-small cell lung, or gastric cancer—who have progressed after standard therapies, to receive investigational BMS-986490 (a first-in-class targeted agent for CEACAM5-expressing malignancies) alone or combined with bevacizumab. Key exclusions include prior anti-CEACAM5 therapy or significant pulmonary toxicity.
ClinicalTrials.gov ID: NCT06730750